During the past decade, Fredrik Piehl conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

In terms of collaborators to trials, out of the total clinical trials conducted in "Fredrik Piehl" #1 collaborator was "Kaiser Foundation Research Institute" with 1 trials as a collaborator and "Patient-Centered Outcomes Research Institute" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Fredrik Piehl" are "Multiple Sclerosis, Relapsing-Remitting" (2 trials) and "Relapsing-remitting Multiple Sclerosis" (1 trials). Many other conditions were trialed in "Fredrik Piehl" in a lesser frequency.

Most popular intervention types in "Fredrik Piehl" are "Drug" (3 trials). Other intervention types were less common.

The name of intervention was led by "Rituximab" (3 trials), "Dimethyl fumarate" (1 trials) and "Sodium Chloride solution" (1 trials). Other intervention names were less common.

The vast majority of trials in "Fredrik Piehl" are 3 trials for "All" genders.

Currently, there are NaN active trials in "Fredrik Piehl". undefined are not yet recruiting, undefined are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Fredrik Piehl, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Fredrik Piehl, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".